DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Bucillamine is an investigational drug.
There have been 5 clinical trials for Bucillamine. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2007.
The most common disease conditions in clinical trials are Arthritis, Arthritis, Rheumatoid, and Cystinuria. The leading clinical trial sponsors are Revive Therapeutics, Ltd., Keio University, and Sanofi.
Recent Clinical Trials for Bucillamine
|Bucillamine in Treatment of Patients With COVID-19||Revive Therapeutics, Ltd.||Phase 3|
|Trial in Patients With Cystinuria||Revive Therapeutics, Ltd.||Phase 2|
|Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout||Revive Therapeutics, Ltd.||Phase 2|